|
|
Blood, 15 April 2008, Vol. 111, No. 8, pp. 4297-4308.
Prepublished online as a Blood First Edition Paper on January 11, 2008; DOI 10.1182/blood-2007-01-068346.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
AML1 mutations induced MDS and MDS/AML in a mouse BMT model
Naoko Watanabe-Okochi1,
Jiro Kitaura1,
Ryoichi Ono1,
Hironori Harada2,
Yuka Harada3,
Yukiko Komeno1,
Hideaki Nakajima1,
Tetsuya Nosaka1,
Toshiya Inaba4, and
Toshio Kitamura1
1 Division of Cellular Therapy, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo;
2 Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima;
3 International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima; and
4 Department of Molecular Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
Myelodysplastic syndrome (MDS) is a hematopoietic stem-cell disorder characterized by trilineage dysplasia and susceptibility to acute myelogenous leukemia (AML). Analysis of molecular basis of MDS has been hampered by the heterogeneity of the disease. Recently, mutations of the transcription factor AML1/RUNX1 have been identified in 15% to 40% of MDS–refractory anemia with excess of blasts (RAEB) and MDS/AML. We performed mouse bone marrow transplantation (BMT) using bone marrow cells transduced with the AML1 mutants. Most mice developed MDS and MDS/AML-like symptoms within 4 to 13 months after BMT. Interestingly, among integration sites identified, Evi1 seemed to collaborate with an AML1 mutant harboring a point mutation in the Runt homology domain (D171N) to induce MDS/AML with an identical phenotype characterized by marked hepatosplenomegaly, myeloid dysplasia, leukocytosis, and biphenotypic surface markers. Collaboration between AML1-D171N and Evi1 was confirmed by a BMT model where coexpression of AML1-D171N and Evi1 induced acute leukemia of the same phenotype with much shorter latencies. On the other hand, a C-terminal truncated AML1 mutant (S291fsX300) induced pancytopenia with erythroid dysplasia in transplanted mice, followed by progression to MDS-RAEB or MDS/AML. Thus, we have developed a useful mouse model of MDS/AML that should help in the understanding of the molecular basis of MDS and the progression of MDS to overt leukemia.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
AML1 and Evi1: coconspirators in MDS/AML?
- Timothy Graubert
Blood 2008 111: 3916-3917.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
A. Tefferi and J. W. Vardiman
Myelodysplastic Syndromes
N. Engl. J. Med.,
November 5, 2009;
361(19):
1872 - 1885.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Konrad, A. Karger, H. Hackl, I. Schwarzinger, I. Herbacek, and R. Wieser
Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes
J. Leukoc. Biol.,
October 1, 2009;
86(4):
813 - 822.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Heuser, D. B. Yap, M. Leung, T. R. de Algara, A. Tafech, S. McKinney, J. Dixon, R. Thresher, B. Colledge, M. Carlton, et al.
Loss of Mll5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation
Blood,
February 12, 2009;
113(7):
1432 - 1443.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Fontenay and E. Gyan
Apoptotic pathways to death in myelodysplastic syndromes
Haematologica,
September 1, 2008;
93(9):
1288 - 1292.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Nimer
MDS: A Stem Cell Disorder--But What Exactly Is Wrong with the Primitive Hematopoietic Cells in This Disease?
Hematology,
January 1, 2008;
2008(1):
43 - 51.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
